{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"description":"MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.","groups":[{"description":"Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-CP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG001","title":"CML-AP With Prior Imatinib Only"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication.\n\nMajor molecular response was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8)","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Participants With (MMR) Major Molecular Response (Phase II)","type":"SECONDARY","unitOfMeasure":"Participants"}